ARQIS advises STAR Capital Partners in conjunction with key nursing home transaction of the year

23. August 2013

ARQIS advised STAR Capital in conjunction with its 100 % divestment of Alloheim Group to The Carlyle Group. Both managing directors, Mr Rainer Hohmann and Mr Thomas Kupczik, continue their investment in the Alloheim Group and will keep managing the Group’s business. According to CARE INVEST, industry news service for the German nursing care market, the transaction is expected to be one of the key nursing care deals in Germany in 2013. The transaction is subject to merger control clearance.

The Alloheim Group continued to grow since the entry of STAR Capital in the year 2008. To this date, the Group grew from originally 13 nursing care homes to 49 homes with around 6,000 beds and over 4,000 employees. Thus, Alloheim became the eight-largest private nursing care operator in Germany in the last five years. ARQIS advised several add-on-transactions for STAR Capital/Alloheim since 2010. In particular, on Alloheim’s landmark deal when it acquired the poli.care/Ensemble-Group in May 2010 (see our press release dated May 11, 2010), by which Alloheim Group grew by 25 homes with around 2,500 beds and doubled its size.

STAR Capital is an independent investment fund manager with over EUR 1 billion of equity funds under management. It was established in 2000 to acquire and develop capital assets and capital asset-based businesses, either independently or in partnership with existing owners/industry partners.

Advisors to STAR Capital

ARQIS Rechtsanwälte: Dr. Jörn-Christian Schulze (Lead), Dr. Christof Alexander Schneider, Dr. Mirjam Boche, Franziska Korn (all M&A/Corporate and Financing); Dr. Andrea Panzer-Heemeier, Eva Trost, Dr. Sebastian Schröder (all Labour Law); Dr. Ulrich Lienhard, Patrick Schöldgen (both Real Estate and Public Law); Beata Brochocki (commercial; all Düsseldorf); Christina Maier (IP); Dr. Michael Reich (Competition/Regulatory; both Munich)

HOW CAN WE HELP YOU?

If you have any questions, please write to us.